Share Price and Basic Stock Data
Last Updated: November 7, 2025, 4:07 pm
| PEG Ratio | 0.72 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Biofil Chemicals & Pharmaceuticals Ltd operates in the pharmaceuticals sector, with a current market capitalization of ₹63.9 Cr and a share price of ₹39.3. The company’s revenue trend has shown fluctuations over the reporting periods, with sales reported at ₹30.04 Cr for the year ending March 2023, rising to ₹40.04 Cr in March 2024. However, preliminary figures for March 2025 indicate a decline to ₹33.40 Cr. Quarterly sales have also varied significantly, with a peak of ₹17.37 Cr recorded in September 2023, followed by a dip to ₹2.43 Cr in June 2023. This variability suggests challenges in maintaining consistent revenue streams, potentially influenced by market conditions or operational inefficiencies. The trailing twelve months (TTM) revenue stood at ₹31.39 Cr, reflecting the need for strategic initiatives to stabilize and enhance revenue generation. Overall, while there are periods of growth, the inconsistency in sales figures raises concerns about the company’s market positioning and operational execution.
Profitability and Efficiency Metrics
Profitability metrics for Biofil Chemicals & Pharmaceuticals Ltd reveal significant challenges. The operating profit margin (OPM) for the year ending March 2025 recorded a modest 2.54%, down from 5.94% in March 2022, indicating a decline in profitability efficiency. The net profit margin also decreased to 1.66% in March 2025 from 3.12% in March 2022, highlighting a struggle to convert sales into profit effectively. Return on equity (ROE) stood at 3.03%, while return on capital employed (ROCE) declined to 4.12%, both of which are relatively low compared to industry standards. The interest coverage ratio (ICR) was robust at 31.24x, suggesting that interest obligations are easily met, but this high ratio could also indicate underutilization of debt for growth. The company’s cash conversion cycle (CCC) was reported at 91.63 days, which reflects inefficiencies in managing working capital, particularly in receivables and inventory management. These profitability and efficiency metrics collectively point to a pressing need for operational improvements to enhance financial performance.
Balance Sheet Strength and Financial Ratios
Biofil Chemicals & Pharmaceuticals Ltd’s balance sheet reflects a conservative financial structure with total borrowings of only ₹0.47 Cr, resulting in a debt-to-equity ratio of 0.02, which is significantly lower than typical industry levels. The company’s reserves increased to ₹2.51 Cr by March 2025, indicating a gradual improvement in retained earnings, which had been negative in prior years. The book value per share stood at ₹11.54, with a P/BV ratio of 3.56x, suggesting that the market values the company’s equity at a premium compared to its book value. The current ratio of 1.34 indicates adequate short-term liquidity, but the quick ratio of 1.23 suggests a reliance on inventory to meet obligations. The enterprise value (EV) was reported at ₹67.15 Cr, compared to the market capitalization, indicating that the market is pricing the company favorably. However, the overall low profitability ratios and the increasing cash conversion cycle present risks to financial health, necessitating stronger operational management to leverage the balance sheet effectively.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Biofil Chemicals & Pharmaceuticals Ltd shows a dominant promoter holding of 46.79%, which remains stable across reporting periods, indicating a consistent commitment from the management. Institutional investor participation is minimal, with foreign institutional investors (FIIs) holding 0% and domestic institutional investors (DIIs) at 0.08%. This lack of institutional interest may reflect concerns about the company’s operational performance and profitability metrics. The public holds 53.12% of shares, with a total of 25,196 shareholders reported, suggesting a reasonably diversified ownership structure. However, the declining trend in the number of shareholders from 28,378 in December 2022 to 25,196 in March 2025 may indicate waning investor confidence. The lack of dividends, as reported, further emphasizes the company’s reinvestment strategy but may also deter potential investors seeking income-generating assets. Overall, while promoter confidence is strong, the limited institutional interest and declining shareholder numbers highlight potential risks to investor sentiment.
Outlook, Risks, and Final Insight
The outlook for Biofil Chemicals & Pharmaceuticals Ltd hinges on its ability to stabilize revenue and enhance profitability. Strengths include a low debt profile, which allows for financial flexibility, and a solid interest coverage ratio that suggests sound financial management in meeting obligations. However, risks are significant, notably the volatility in sales and profitability metrics, which could hinder growth and investor confidence. Additionally, the company’s reliance on a small public base and lack of institutional investment may limit its access to capital for expansion. The increasing cash conversion cycle also presents operational challenges that need addressing. In scenarios where operational efficiencies are improved and revenue stabilizes, the company could potentially enhance its market position. Conversely, continued revenue fluctuations and low profitability could lead to further declines in investor sentiment. Overall, the company must prioritize operational improvements and strategic growth initiatives to foster a more favorable outlook.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Biofil Chemicals & Pharmaceuticals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 142 Cr. | 113 | 247/84.3 | 32.4 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,887 Cr. | 449 | 479/192 | 110 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.8 Cr. | 44.2 | 92.2/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 36.5 Cr. | 24.9 | 29.1/17.0 | 38.0 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,624.49 Cr | 1,183.00 | 56.65 | 197.01 | 0.34% | 16.24% | 14.95% | 6.10 |
All Competitor Stocks of Biofil Chemicals & Pharmaceuticals Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.31 | 2.62 | 1.49 | 13.62 | 2.43 | 17.37 | 5.03 | 15.20 | 8.44 | 2.41 | 14.20 | 8.35 | 6.43 |
| Expenses | 11.94 | 2.46 | 1.26 | 13.21 | 2.01 | 17.13 | 4.84 | 15.24 | 8.13 | 2.29 | 13.89 | 8.24 | 6.42 |
| Operating Profit | 0.37 | 0.16 | 0.23 | 0.41 | 0.42 | 0.24 | 0.19 | -0.04 | 0.31 | 0.12 | 0.31 | 0.11 | 0.01 |
| OPM % | 3.01% | 6.11% | 15.44% | 3.01% | 17.28% | 1.38% | 3.78% | -0.26% | 3.67% | 4.98% | 2.18% | 1.32% | 0.16% |
| Other Income | 0.02 | 0.02 | 0.02 | 0.03 | 0.02 | 0.03 | 0.03 | 0.41 | 0.03 | 0.02 | 0.02 | 0.24 | 2.83 |
| Interest | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Depreciation | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.08 | 0.10 | 0.10 | 0.10 | 0.08 | 0.07 |
| Profit before tax | 0.27 | 0.06 | 0.13 | 0.32 | 0.32 | 0.15 | 0.11 | 0.27 | 0.23 | 0.03 | 0.22 | 0.26 | 2.76 |
| Tax % | 25.93% | 33.33% | 23.08% | 34.38% | 25.00% | 20.00% | 18.18% | 11.11% | 26.09% | 33.33% | 27.27% | 23.08% | 12.68% |
| Net Profit | 0.21 | 0.05 | 0.10 | 0.21 | 0.24 | 0.12 | 0.09 | 0.25 | 0.17 | 0.02 | 0.16 | 0.20 | 2.41 |
| EPS in Rs | 0.13 | 0.03 | 0.06 | 0.13 | 0.15 | 0.07 | 0.06 | 0.15 | 0.10 | 0.01 | 0.10 | 0.12 | 1.48 |
Last Updated: August 20, 2025, 12:45 pm
Below is a detailed analysis of the quarterly data for Biofil Chemicals & Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 6.43 Cr.. The value appears to be declining and may need further review. It has decreased from 8.35 Cr. (Mar 2025) to 6.43 Cr., marking a decrease of 1.92 Cr..
- For Expenses, as of Jun 2025, the value is 6.42 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 8.24 Cr. (Mar 2025) to 6.42 Cr., marking a decrease of 1.82 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.11 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.10 Cr..
- For OPM %, as of Jun 2025, the value is 0.16%. The value appears to be declining and may need further review. It has decreased from 1.32% (Mar 2025) to 0.16%, marking a decrease of 1.16%.
- For Other Income, as of Jun 2025, the value is 2.83 Cr.. The value appears strong and on an upward trend. It has increased from 0.24 Cr. (Mar 2025) to 2.83 Cr., marking an increase of 2.59 Cr..
- For Interest, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Depreciation, as of Jun 2025, the value is 0.07 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.08 Cr. (Mar 2025) to 0.07 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 2.76 Cr.. The value appears strong and on an upward trend. It has increased from 0.26 Cr. (Mar 2025) to 2.76 Cr., marking an increase of 2.50 Cr..
- For Tax %, as of Jun 2025, the value is 12.68%. The value appears to be improving (decreasing) as expected. It has decreased from 23.08% (Mar 2025) to 12.68%, marking a decrease of 10.40%.
- For Net Profit, as of Jun 2025, the value is 2.41 Cr.. The value appears strong and on an upward trend. It has increased from 0.20 Cr. (Mar 2025) to 2.41 Cr., marking an increase of 2.21 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.48. The value appears strong and on an upward trend. It has increased from 0.12 (Mar 2025) to 1.48, marking an increase of 1.36.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 5:29 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.17 | 5.86 | 13.17 | 13.45 | 12.36 | 23.13 | 29.69 | 35.75 | 22.38 | 30.04 | 40.04 | 33.40 | 31.39 |
| Expenses | 6.21 | 5.12 | 12.30 | 10.84 | 11.43 | 22.11 | 27.87 | 34.15 | 21.05 | 28.88 | 39.23 | 32.55 | 30.84 |
| Operating Profit | 0.96 | 0.74 | 0.87 | 2.61 | 0.93 | 1.02 | 1.82 | 1.60 | 1.33 | 1.16 | 0.81 | 0.85 | 0.55 |
| OPM % | 13.39% | 12.63% | 6.61% | 19.41% | 7.52% | 4.41% | 6.13% | 4.48% | 5.94% | 3.86% | 2.02% | 2.54% | 1.75% |
| Other Income | 0.06 | 0.46 | 0.53 | 0.14 | 0.10 | 0.10 | 0.17 | 0.80 | 0.15 | 0.10 | 0.49 | 0.31 | 3.11 |
| Interest | 0.15 | 0.21 | 0.15 | 0.16 | 0.15 | 0.16 | 0.12 | 0.07 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Depreciation | 0.22 | 0.25 | 0.26 | 0.28 | 0.30 | 0.37 | 0.41 | 0.41 | 0.43 | 0.43 | 0.40 | 0.38 | 0.35 |
| Profit before tax | 0.65 | 0.74 | 0.99 | 2.31 | 0.58 | 0.59 | 1.46 | 1.92 | 1.01 | 0.79 | 0.86 | 0.74 | 3.27 |
| Tax % | 20.00% | 20.27% | 20.20% | 22.51% | 20.69% | 20.34% | 17.81% | 34.90% | 31.68% | 29.11% | 17.44% | 24.32% | |
| Net Profit | 0.52 | 0.59 | 0.78 | 1.79 | 0.47 | 0.48 | 1.21 | 1.24 | 0.70 | 0.56 | 0.71 | 0.56 | 2.79 |
| EPS in Rs | 0.32 | 0.36 | 0.48 | 1.10 | 0.29 | 0.29 | 0.74 | 0.76 | 0.43 | 0.34 | 0.44 | 0.34 | 1.71 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 13.46% | 32.20% | 129.49% | -73.74% | 2.13% | 152.08% | 2.48% | -43.55% | -20.00% | 26.79% | -21.13% |
| Change in YoY Net Profit Growth (%) | 0.00% | 18.74% | 97.28% | -203.23% | 75.87% | 149.96% | -149.60% | -46.03% | 23.55% | 46.79% | -47.91% |
Biofil Chemicals & Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 2% |
| 3 Years: | 14% |
| TTM: | -32% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -14% |
| 3 Years: | -7% |
| TTM: | 343% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 5% |
| 3 Years: | -7% |
| 1 Year: | -32% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 4% |
| 3 Years: | 3% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 1:00 am
Balance Sheet
Last Updated: September 10, 2025, 1:34 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 |
| Reserves | -8.41 | -7.86 | -5.37 | -3.58 | -3.11 | -2.62 | -1.39 | -0.14 | 0.56 | 1.03 | 1.93 | 2.51 |
| Borrowings | 2.87 | 2.98 | 1.37 | 1.43 | 1.56 | 1.64 | 1.19 | 0.43 | 0.46 | 0.52 | 0.44 | 0.47 |
| Other Liabilities | 3.87 | 2.36 | 11.87 | 7.72 | 9.44 | 8.93 | 26.30 | 16.68 | 1.44 | 13.58 | 28.44 | 31.70 |
| Total Liabilities | 14.60 | 13.75 | 24.14 | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.40 | 47.08 | 50.95 |
| Fixed Assets | 9.17 | 9.06 | 8.98 | 9.16 | 9.25 | 10.29 | 10.09 | 9.78 | 9.42 | 9.00 | 8.62 | 8.34 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 5.43 | 4.69 | 15.16 | 12.68 | 14.91 | 13.93 | 32.28 | 23.46 | 9.31 | 22.40 | 38.46 | 42.61 |
| Total Assets | 14.60 | 13.75 | 24.14 | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.40 | 47.08 | 50.95 |
Below is a detailed analysis of the balance sheet data for Biofil Chemicals & Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 16.27 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 16.27 Cr..
- For Reserves, as of Mar 2025, the value is 2.51 Cr.. The value appears strong and on an upward trend. It has increased from 1.93 Cr. (Mar 2024) to 2.51 Cr., marking an increase of 0.58 Cr..
- For Borrowings, as of Mar 2025, the value is 0.47 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.44 Cr. (Mar 2024) to 0.47 Cr., marking an increase of 0.03 Cr..
- For Other Liabilities, as of Mar 2025, the value is 31.70 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 28.44 Cr. (Mar 2024) to 31.70 Cr., marking an increase of 3.26 Cr..
- For Total Liabilities, as of Mar 2025, the value is 50.95 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 47.08 Cr. (Mar 2024) to 50.95 Cr., marking an increase of 3.87 Cr..
- For Fixed Assets, as of Mar 2025, the value is 8.34 Cr.. The value appears to be declining and may need further review. It has decreased from 8.62 Cr. (Mar 2024) to 8.34 Cr., marking a decrease of 0.28 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 42.61 Cr.. The value appears strong and on an upward trend. It has increased from 38.46 Cr. (Mar 2024) to 42.61 Cr., marking an increase of 4.15 Cr..
- For Total Assets, as of Mar 2025, the value is 50.95 Cr.. The value appears strong and on an upward trend. It has increased from 47.08 Cr. (Mar 2024) to 50.95 Cr., marking an increase of 3.87 Cr..
Notably, the Reserves (2.51 Cr.) exceed the Borrowings (0.47 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.91 | -2.24 | -0.50 | 1.18 | -0.63 | -0.62 | 0.63 | 1.17 | 0.87 | 0.64 | 0.37 | 0.38 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 208.72 | 227.35 | 387.45 | 311.00 | 383.31 | 189.84 | 365.25 | 175.81 | 116.94 | 249.08 | 301.10 | 418.77 |
| Inventory Days | 20.53 | 15.99 | 3.46 | 7.29 | 38.11 | 21.73 | 24.37 | 48.85 | 24.20 | 16.11 | 24.81 | 39.52 |
| Days Payable | 276.79 | 198.49 | 400.98 | 304.52 | 341.46 | 156.66 | 373.80 | 178.39 | 11.25 | 168.39 | 268.08 | 366.66 |
| Cash Conversion Cycle | -47.54 | 44.85 | -10.07 | 13.76 | 79.95 | 54.90 | 15.82 | 46.27 | 129.88 | 96.80 | 57.83 | 91.63 |
| Working Capital Days | -75.85 | -47.96 | 48.50 | 87.65 | 104.83 | 50.81 | 55.69 | 64.12 | 125.25 | 104.25 | 69.37 | 114.09 |
| ROCE % | 7.66% | 8.59% | 9.64% | 18.72% | 5.06% | 5.00% | 10.08% | 12.20% | 6.20% | 4.73% | 4.94% | 4.12% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.34 | 0.44 | 0.34 | 0.44 | 0.76 |
| Diluted EPS (Rs.) | 0.34 | 0.44 | 0.34 | 0.44 | 0.76 |
| Cash EPS (Rs.) | 0.57 | 0.68 | 0.60 | 0.69 | 1.01 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 11.54 | 11.19 | 10.63 | 10.35 | 9.91 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 11.54 | 11.19 | 10.63 | 10.35 | 9.91 |
| Revenue From Operations / Share (Rs.) | 20.52 | 24.60 | 18.46 | 13.75 | 21.97 |
| PBDIT / Share (Rs.) | 0.70 | 0.80 | 0.77 | 0.91 | 1.47 |
| PBIT / Share (Rs.) | 0.47 | 0.55 | 0.51 | 0.64 | 1.22 |
| PBT / Share (Rs.) | 0.45 | 0.53 | 0.48 | 0.62 | 1.18 |
| Net Profit / Share (Rs.) | 0.34 | 0.43 | 0.34 | 0.42 | 0.76 |
| PBDIT Margin (%) | 3.45 | 3.26 | 4.21 | 6.62 | 6.71 |
| PBIT Margin (%) | 2.31 | 2.26 | 2.78 | 4.71 | 5.55 |
| PBT Margin (%) | 2.20 | 2.16 | 2.64 | 4.53 | 5.36 |
| Net Profit Margin (%) | 1.66 | 1.77 | 1.86 | 3.12 | 3.47 |
| Return on Networth / Equity (%) | 2.96 | 3.89 | 3.23 | 4.14 | 7.69 |
| Return on Capital Employeed (%) | 4.04 | 4.88 | 4.72 | 6.12 | 12.05 |
| Return On Assets (%) | 1.09 | 1.50 | 1.78 | 3.72 | 3.73 |
| Total Debt / Equity (X) | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 |
| Asset Turnover Ratio (%) | 0.68 | 1.02 | 1.20 | 0.86 | 0.94 |
| Current Ratio (X) | 1.34 | 1.35 | 1.63 | 6.23 | 1.40 |
| Quick Ratio (X) | 1.23 | 1.26 | 1.54 | 5.37 | 1.14 |
| Inventory Turnover Ratio (X) | 11.34 | 2.79 | 3.13 | 0.80 | 2.27 |
| Interest Coverage Ratio (X) | 31.24 | 31.47 | 29.76 | 36.53 | 35.23 |
| Interest Coverage Ratio (Post Tax) (X) | 16.11 | 18.09 | 14.19 | 18.20 | 19.23 |
| Enterprise Value (Cr.) | 67.15 | 96.38 | 67.93 | 94.38 | 106.83 |
| EV / Net Operating Revenue (X) | 2.01 | 2.41 | 2.26 | 4.22 | 2.99 |
| EV / EBITDA (X) | 58.26 | 73.79 | 53.71 | 63.64 | 44.53 |
| MarketCap / Net Operating Revenue (X) | 2.00 | 2.45 | 2.25 | 4.20 | 2.99 |
| Price / BV (X) | 3.56 | 5.40 | 3.90 | 5.59 | 6.62 |
| Price / Net Operating Revenue (X) | 2.00 | 2.45 | 2.25 | 4.20 | 2.99 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Biofil Chemicals & Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 5. It has decreased from 0.44 (Mar 24) to 0.34, marking a decrease of 0.10.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 5. It has decreased from 0.44 (Mar 24) to 0.34, marking a decrease of 0.10.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 3. It has decreased from 0.68 (Mar 24) to 0.57, marking a decrease of 0.11.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.54. It has increased from 11.19 (Mar 24) to 11.54, marking an increase of 0.35.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.54. It has increased from 11.19 (Mar 24) to 11.54, marking an increase of 0.35.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 20.52. It has decreased from 24.60 (Mar 24) to 20.52, marking a decrease of 4.08.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.70. This value is below the healthy minimum of 2. It has decreased from 0.80 (Mar 24) to 0.70, marking a decrease of 0.10.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.47. This value is within the healthy range. It has decreased from 0.55 (Mar 24) to 0.47, marking a decrease of 0.08.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.45. This value is within the healthy range. It has decreased from 0.53 (Mar 24) to 0.45, marking a decrease of 0.08.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 2. It has decreased from 0.43 (Mar 24) to 0.34, marking a decrease of 0.09.
- For PBDIT Margin (%), as of Mar 25, the value is 3.45. This value is below the healthy minimum of 10. It has increased from 3.26 (Mar 24) to 3.45, marking an increase of 0.19.
- For PBIT Margin (%), as of Mar 25, the value is 2.31. This value is below the healthy minimum of 10. It has increased from 2.26 (Mar 24) to 2.31, marking an increase of 0.05.
- For PBT Margin (%), as of Mar 25, the value is 2.20. This value is below the healthy minimum of 10. It has increased from 2.16 (Mar 24) to 2.20, marking an increase of 0.04.
- For Net Profit Margin (%), as of Mar 25, the value is 1.66. This value is below the healthy minimum of 5. It has decreased from 1.77 (Mar 24) to 1.66, marking a decrease of 0.11.
- For Return on Networth / Equity (%), as of Mar 25, the value is 2.96. This value is below the healthy minimum of 15. It has decreased from 3.89 (Mar 24) to 2.96, marking a decrease of 0.93.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.04. This value is below the healthy minimum of 10. It has decreased from 4.88 (Mar 24) to 4.04, marking a decrease of 0.84.
- For Return On Assets (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 5. It has decreased from 1.50 (Mar 24) to 1.09, marking a decrease of 0.41.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.68. It has decreased from 1.02 (Mar 24) to 0.68, marking a decrease of 0.34.
- For Current Ratio (X), as of Mar 25, the value is 1.34. This value is below the healthy minimum of 1.5. It has decreased from 1.35 (Mar 24) to 1.34, marking a decrease of 0.01.
- For Quick Ratio (X), as of Mar 25, the value is 1.23. This value is within the healthy range. It has decreased from 1.26 (Mar 24) to 1.23, marking a decrease of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 11.34. This value exceeds the healthy maximum of 8. It has increased from 2.79 (Mar 24) to 11.34, marking an increase of 8.55.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 31.24. This value is within the healthy range. It has decreased from 31.47 (Mar 24) to 31.24, marking a decrease of 0.23.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 16.11. This value is within the healthy range. It has decreased from 18.09 (Mar 24) to 16.11, marking a decrease of 1.98.
- For Enterprise Value (Cr.), as of Mar 25, the value is 67.15. It has decreased from 96.38 (Mar 24) to 67.15, marking a decrease of 29.23.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has decreased from 2.41 (Mar 24) to 2.01, marking a decrease of 0.40.
- For EV / EBITDA (X), as of Mar 25, the value is 58.26. This value exceeds the healthy maximum of 15. It has decreased from 73.79 (Mar 24) to 58.26, marking a decrease of 15.53.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 2.45 (Mar 24) to 2.00, marking a decrease of 0.45.
- For Price / BV (X), as of Mar 25, the value is 3.56. This value exceeds the healthy maximum of 3. It has decreased from 5.40 (Mar 24) to 3.56, marking a decrease of 1.84.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 2.45 (Mar 24) to 2.00, marking a decrease of 0.45.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Biofil Chemicals & Pharmaceuticals Ltd:
- Net Profit Margin: 1.66%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.04% (Industry Average ROCE: 16.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 2.96% (Industry Average ROE: 14.47%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 16.11
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.23
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 23 (Industry average Stock P/E: 47.51)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.66%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | B/12-B Industrial Estate, Pologround, Indore Madhya Pradesh 452015 | bcplcompliance@gmail.com http://www.biofilgroup.net |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ketan Shah | Chairman & Managing Director |
| Mr. Smitesh Shah | Non Exe.Non Ind.Director |
| Mr. Meet Shah | Non Exe.Non Ind.Director |
| Mr. Satish Beohar | Ind. Non-Executive Director |
| Mr. Ashok Kumar Ramawat | Ind. Non-Executive Director |
| Mrs. Gayatri Padiyar | Ind. Non-Executive Woman Director |
FAQ
What is the intrinsic value of Biofil Chemicals & Pharmaceuticals Ltd?
Biofil Chemicals & Pharmaceuticals Ltd's intrinsic value (as of 07 November 2025) is 6.54 which is 83.40% lower the current market price of 39.40, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 64.0 Cr. market cap, FY2025-2026 high/low of 72.0/37.7, reserves of ₹2.51 Cr, and liabilities of 50.95 Cr.
What is the Market Cap of Biofil Chemicals & Pharmaceuticals Ltd?
The Market Cap of Biofil Chemicals & Pharmaceuticals Ltd is 64.0 Cr..
What is the current Stock Price of Biofil Chemicals & Pharmaceuticals Ltd as on 07 November 2025?
The current stock price of Biofil Chemicals & Pharmaceuticals Ltd as on 07 November 2025 is 39.4.
What is the High / Low of Biofil Chemicals & Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Biofil Chemicals & Pharmaceuticals Ltd stocks is 72.0/37.7.
What is the Stock P/E of Biofil Chemicals & Pharmaceuticals Ltd?
The Stock P/E of Biofil Chemicals & Pharmaceuticals Ltd is 23.0.
What is the Book Value of Biofil Chemicals & Pharmaceuticals Ltd?
The Book Value of Biofil Chemicals & Pharmaceuticals Ltd is 11.5.
What is the Dividend Yield of Biofil Chemicals & Pharmaceuticals Ltd?
The Dividend Yield of Biofil Chemicals & Pharmaceuticals Ltd is 0.00 %.
What is the ROCE of Biofil Chemicals & Pharmaceuticals Ltd?
The ROCE of Biofil Chemicals & Pharmaceuticals Ltd is 4.12 %.
What is the ROE of Biofil Chemicals & Pharmaceuticals Ltd?
The ROE of Biofil Chemicals & Pharmaceuticals Ltd is 3.03 %.
What is the Face Value of Biofil Chemicals & Pharmaceuticals Ltd?
The Face Value of Biofil Chemicals & Pharmaceuticals Ltd is 10.0.